Table 3

Characteristics of the patients with AF received OAC or not at discharge

OAC treatment (n=62)Non-OAC treatment (n=224)
Age (year)69 (57, 77)68 (59, 76)
Sex (female (%))30 (48.4)98 (43.8)
Smoking (n(%))16 (25.8)50 (22.3)
Hypertension (n(%))32 (51.6)91 (40.6)
Diabetes mellitus (n(%))19 (30.6)46 (20.5)
Dyslipidaemia (n(%))20 (32.3)83 (37.1)
Abnormal renal (n(%))5 (8.1)14 (6.3)
Abnormal liver function (n(%))1 (1.6)4 (1.8)
Non-steroidal anti-inflammatory drugs/alcohol abuse (n(%))4 (6.5)21 (9.4)
Killip classification III–IV (n(%))21 (33.9)63 (28.1)
History of stroke (n(%))8 (12.9)*9 (4.0)
History of bleeding (n(%))2 (3.2)19 (8.5)
AMI (n(%))25 (40.3)90 (40.2)
CHA2DS2-VASc score ≥2 (n(%))61 (98.4)212 (94.6)
HAS-BLED score ≥3 (n(%))12 (19.4)**79 (35.3)
Persistent/permanent AF (n(%))59 (95.2)**168 (75)
Pre-admission use of OAC (n(%))19 (30.6)**7 (3.1)
  • *P<0.05 versus ‘non-OAC’ group. **P<0.01 versus ‘non-OAC’ group.

  • AF, atrial fibrillation; AMI, acute myocardial infarction; OAC, oral anticoagulant.